Results 121 to 130 of about 4,259,087 (330)
HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action
HDACs are critical regulators of gene expression that function through histone modification. Non-histone proteins and histones are targeted by these proteins and the inhibition of HDACs results in various biological effects.
Y. Imai +4 more
semanticscholar +1 more source
Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu +5 more
wiley +1 more source
Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas
Purpose: Both gain-of-function enhancer of zeste homolog 2 (EZH2) mutations and inactivating histone acetyltransferases mutations, such as CREBBP and EP300, have been implicated in the pathogenesis of germinal center (GC)–derived lymphomas.
J. Lue +15 more
semanticscholar +1 more source
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen +9 more
wiley +1 more source
In the past two decades, targeted cancer therapy has emerged as a novel class of anticancer therapeutics, besides traditional chemotherapy, surgery, and radiotherapy.
Shweta Mishra +4 more
doaj +1 more source
Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer
SUMMARY ARID1A , a subunit of the SWI/SNF complex, is among the most frequently mutated genes across cancer types. ARID1A is mutated in more than 50% of ovarian clear cell carcinomas (OCCCs), diseases that have no effective therapy.
Takeshi Fukumoto +14 more
semanticscholar +1 more source
Harnessing bacterial extracellular vesicles for bone and cartilage organoids
This review presents bacterial extracellular vesicles (BEVs) as programmable bioactive regulators for bone and cartilage organoids by delivering functional cargos that modulate skeletal remodeling. It highlights key engineering strategies and future directions to advance next‐generation organoid models for bone aging related diseases.
Han Liu +8 more
wiley +1 more source
This review systematically summarizes the major molecular mechanisms governing TAM polarization and their coordinated interactions. It further highlights recent advances in nanoagonist‐based strategies that intervene in these pathways to reprogram TAMs, critically discussing their therapeutic potential, current limitations, and translational prospects.
Siqi Fang +7 more
wiley +1 more source
ABSTRACT The cytoskeleton of striated muscle integrates force transmission, mechanotransduction, and sarcolemmal stability through coordinated networks of sarcomeres, costameres, and intermediate filaments. Together, these systems establish mechanical continuity between the contractile apparatus, the sarcolemma, and the extracellular matrix.
Houda Cohen +3 more
wiley +1 more source
Carbamates as Potential Prodrugs and a New Warhead for HDAC Inhibition
We designed and synthesized carbamates of the clinically-approved HDAC (histone deacetylase) inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in order to validate our previously-proposed hypothesis that these carbamates might serve as ...
Kristina King +4 more
doaj +1 more source

